NCT07459543 2026-03-09
A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India
Bristol-Myers Squibb
Phase 4 Not yet recruiting
Clinical Trials
12 trialsNCT07028125 2025-10-07
CANIQOL
Centre Francois Baclesse
Phase 4 Recruiting
NCT06934057 2025-09-24
CABOLD
Gustave Roussy, Cancer Campus, Grand Paris
Phase 4 Recruiting
NCT04513522 2025-07-11
CheckMate 7C9
Bristol-Myers Squibb
Phase 4 Completed
NCT06031233 2025-05-21
MINUTE
Isala
Phase 4 Recruiting
NCT06116461 2024-04-22
NIVOPTIMIZE
Erasmus Medical Center
Phase 4 Recruiting
NCT02869789 2023-06-15
An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers
Bristol-Myers Squibb
Phase 4 Completed
NCT03313544 2023-04-21
Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1
Assistance Publique Hopitaux De Marseille
Phase 4 Unknown
NCT02982954 2022-11-01
CHECKMATE 920
Bristol-Myers Squibb
Phase 4 Completed
NCT02596035 2022-10-27
CheckMate 374
Bristol-Myers Squibb
Phase 4 Completed
NCT04707547 2021-01-13
RFA
Taipei Medical University WanFang Hospital
Phase 4 Completed
NCT04331626 2020-04-02
Low-dose Gemcitabine Combined With Nivolumab for Second-line and Above Line Treatment of NSCLC
Henan Cancer Hospital
Phase 4 Unknown